abstract details

The summaries are free for public use. ARTHROS will continue to add and archive summaries of articles deemed relevant to ARTHROS by our Faculty.

The Future of Axial Spondyloathritis Treatment

Author

Rheum Dis Clin North Am. 2020 May;46(2):357-365. doi: 10.1016/j.rdc.2020.01.014.

Sinead Maguire 1, Raj Sengupta 2, Finbar O'Shea 3

Author Information

1. Department of Rheumatology, St James' Hospital, Ushers Quay, Dublin D08 NHY1, Ireland.

2. Royal National Hospital for Rheumatic Diseases, Royal United Hospitals, Combe Park, Bath BA1 3NG, UK.

3. Department of Rheumatology, St James' Hospital, Ushers Quay, Dublin D08 NHY1, Ireland. Electronic address: FOShea@STJAMES.IE.

Abstract

Axial spondyloathritis (axSpA) treatment with biologic DMARDs was previously focused around anti-TNF agents. Significant advances in research have led to new therapeutic options, such as secukinumab, an IL-17 inhibitor, which has been approved for the treatment of axSpA. Two other biologic agents that are already licensed for rheumatoid and psoriatic arthritis, tofacitinib and ixekizumab, have demonstrated improved outcomes in axSpA. Several newer agents have been developed to inhibit IL-17, IL-23, and JAK. Early trials are promising; however, further research is needed. Rapid expansion of therapies available to treat axSpA could lead to improved disease control and decreased disease burden.